Cholesterol-lowering drugs should revolutionise treatment of heart attack and stroke

July 04, 2002

Results of a landmark study published in the July 6 issue of THE LANCET highlight how the prescribing of statins to lower blood cholesterol could reduce rates of heart attack and stroke by at least a third.

Vascular disease is the leading cause of death in many countries. Statins are usually only given to people who have heart disease and raised blood cholesterol. New findings from the Heart Protection Study (HPS) led by Rory Collins from the University of Oxford's Clinical Trial Service Unit show that statins also reduce the risk of heart attack and stroke in people who have diabetes, arterial disease, or in individuals who have previously had a stroke. Most strikingly, the study found substantial benefits even among those high-risk patients considered to have "normal" or "low" blood cholesterol concentrations. The HPS study provides definite evidence that guidelines should be changed so that a statin is considered for anybody at an increased risk of heart attack or stroke-regardless of their blood cholesterol concentration.

Over 20,000 UK adults (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive daily doses of 40 mg simvastatin or placebo for five years. Death from all causes was reduced from 14.7% (for patients given placebo) to 12.9% (for patients given simvastatin), mainly due to an 18% relative reduction in the coronary death rate in patients assigned simvastatin.

There were also relative reductions of around 25% for non-fatal heart attack or coronary death, for non-fatal or fatal stroke, and for coronary or non-coronary revascularisation. Simvastatin was well tolerated with no major side-effects, and its benefits were additional to those of other cardioprotective treatments such as aspirin, - -blockers, and ACE inhibitors.

HPS also assessed the effects of using antioxidant vitamin supplements (600mg vitamin E, 250mg vitamin C and 20mg beta-carotene daily) in people at high risk of vascular disease. Vitamin supplementation did not produce any significant reductions in the five-year risk of heart attack, stroke, cancer, or other major outcomes.

Rory Collins comments: " HPS shows unequivocally that statins can produce substantial benefit in a very much wider range of high-risk people than had been previously thought. These new findings are relevant to the treatment of some hundreds of millions of people worldwide. If now, as a result, an extra 10 million high-risk people were to go onto statin treatment, this would save about 50,000 lives a year-that's a thousand each week. In addition, this would prevent similar numbers of people from suffering non-fatal heart attack or stroke."

Richard Horton, Editor of THE LANCET, comments: "These findings should tear up the rule-book on statin prescribing. They are the most important and far-reaching results for the treatment and prevention of heart disease and stroke that we have seen in a generation. They should result in a dramatic change in clinical practice around the world. Previously there has been concern that statins have been used too much; after the results of HPS have been published there should be concern that they may not be used enough in the future."

In an accompanying Commentary (p 2), Salim Yusuf from McMaster University, Hamilton, Canada, concludes: "The past 25 years have seen the establishment of aspirin, ß-blockers, ACE-inhibitors, and lipid-lowering therapies to prevent the risk of future vascular events by about a quarter each, in high-risk patients. The benefits of each intervention appear to be largely independent, so that when used together in appropriate patients, it is reasonable to expect that about two-thirds to three-quarters of future vascular events could be prevented. Add to this the potential benefits of quitting in smokers (which lowers the risk of myocardial infarction by a half), and blood-pressure lowering (a 10 mm Hg reduction in systolic blood pressure could reduce the risk of vascular events by a quarter) in hypertensive patients, and it may be possible to lower the risk of future events by more than four-fifths in high-risk individuals. Therefore, the potential gains from the combination of currently known preventive strategies are large. Given that over 80% of cardiovascular disease occurs in developing countries, a priority is to make these interventions affordable, accessible, and convenient (perhaps even a combination pill). Ensuring that patients worldwide receive these treatments will lead to substantial clinical and public-health benefits."
-end-
** PRESS CONFERENCE ** - The main findings and public-health implications of the HPS study will be presented at 1000 H (UK time) on Thursday 4 July 2002 at the Royal Society of Medicine, London, UK. Further information from Richard Lane, The Lancet Press Office, T) +44 (0)20 7424 4949; E) richard.lane@lancet.com

Contacts: Chris Bray [CTSU] T) +44(0) 1865 404815; E) chris.bray@ctsu.ox.ac.uk

Margaret Willson [CTSU] T) from 29 June-3 July +43 (0) 1 260 69 2010/2011; M) +44 (0) 7973 853347; E) m.willson@mwcommunications.org.uk

Richard Lane (The Lancet), T) +44 (0)20 7424 4949; E) Richard.lane@lancet.com

Jo Hudson (British Heart Foundation) T) +44 (0) 20 7487 7178; E) hudsonj@bhf.org.uk

Professor Salim Yusuf, Population Health Research Institute, McMaster University, Hamilton, Ontario, L8L 2X2, Canada; T) +1 905 527 7327; F) +1 905 521 1166; E) yusufs@mcmaster.ca

Lancet

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.